Stockscreener 앱 받기
13.62
1.02%
-0.14
전일 마감가:
$13.76
열려 있는:
$13.89
하루 거래량:
637.67K
Relative Volume:
1.00
시가총액:
$689.49M
수익:
$89.04M
순이익/손실:
$-241.08M
주가수익비율:
-2.5894
EPS:
-5.26
순현금흐름:
$-194.72M
1주 성능:
-6.65%
1개월 성능:
-3.47%
6개월 성능:
+60.24%
1년 성능:
+90.49%
1일 변동 폭
$13.56
$14.22
1주일 범위
$13.56
$15.84
52주 변동 폭
$5.035
$15.84
Regenxbio Inc Stock (RGNX) Company Profile
명칭
Regenxbio Inc
전화
240-552-8181
주소
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
RGNX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
13.62 | 696.57M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-11 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-02-07 | 재개 | Raymond James | Outperform |
| 2024-11-15 | 재개 | Morgan Stanley | Overweight |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-06-07 | 개시 | Goldman | Buy |
| 2024-03-11 | 개시 | H.C. Wainwright | Buy |
| 2024-03-08 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | 재개 | Raymond James | Outperform |
| 2023-11-01 | 개시 | Stifel | Buy |
| 2023-06-02 | 개시 | Robert W. Baird | Outperform |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-12-15 | 개시 | Wedbush | Neutral |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-01-06 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | 재확인 | Chardan Capital Markets | Buy |
| 2019-06-14 | 재개 | Raymond James | Outperform |
| 2019-06-05 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-25 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-02-05 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | 재확인 | Chardan Capital Markets | Buy |
| 2018-11-08 | 재확인 | BofA/Merrill | Neutral |
| 2018-08-08 | 재확인 | Chardan Capital Markets | Buy |
| 2018-07-23 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | 재확인 | Chardan Capital Markets | Buy |
| 2018-05-09 | 재확인 | Barclays | Overweight |
| 2018-04-09 | 재확인 | Chardan Capital Markets | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-02-13 | 개시 | Mizuho | Neutral |
| 2017-11-09 | 재개 | Morgan Stanley | Overweight |
모두보기
Regenxbio Inc 주식(RGNX)의 최신 뉴스
Street Watch: Is REGENXBIO Inc impacted by rising ratesQuarterly Portfolio Summary & Low Risk Entry Point Guides - baoquankhu1.vn
Regenxbio Shares Retreat as Market Digests Conflicting Signals - AD HOC NEWS
REGENXBIO (NASDAQ:RGNX) Stock Price Down 6.7%What's Next? - MarketBeat
Patients Treated With REGENXBIO’s DMD Gene Therapy RGX-202 Exceed Expected Disease Trajectory on NSAA - NeurologyLive
Is REGENXBIO Inc in a long term uptrendPrice Action & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
RGNX: Pivotal data and regulatory milestones in Duchenne, wet AMD, and Hunter programs drive a transformative year - TradingView — Track All Markets
RGNX: Late-stage gene therapy programs show strong efficacy, safety, and commercial readiness for 2024 - TradingView — Track All Markets
$191.2 Million Achromatopsia Market Outlook, 2026-2032, - GlobeNewswire
$191.2 Million Achromatopsia Market Outlook, 2026-2032, Featuring Adverum Biotechnologies, Homology Medicines, Mattel, REGENXBIO, Sanofi and More - Yahoo Finance
Is REGENXBIO Inc stock undervalued right nowJuly 2025 Highlights & Technical Pattern Based Buy Signals - baoquankhu1.vn
Technical Reactions to RGNX Trends in Macro Strategies - Stock Traders Daily
REGENXBIO (NASDAQ:RGNX) Sets New 12-Month HighHere's Why - MarketBeat
Macular Degeneration Treatment Market is expected to reach US$ - openPR.com
Hedge Fund Moves: What hedge fund activity signals for REGENXBIO Inc. stockMarket Sentiment Review & Fast Exit and Entry Trade Guides - Bộ Nội Vụ
Market Overview: Is REGENXBIO Inc stock undervalued right now2025 Price Action Summary & Fast Gain Swing Alerts - baoquankhu1.vn
Lobbying Update: $60,000 of REGENXBIO INC. lobbying was just disclosed - Quiver Quantitative
REGENXBIO (NASDAQ:RGNX) Shares Gap UpShould You Buy? - MarketBeat
Regenxbio (RGNX) Shares Rise on Promising Duchenne Therapy Data - GuruFocus
Regenxbio stock maintains Buy rating at H.C. Wainwright on positive DMD trial data - Investing.com Nigeria
REGENXBIO Stock Hits New High On Duchenne Trial DataWill 2026 Be A Transformative Year? - RTTNews
Regenxbio stock rating reiterated at Outperform by Baird on positive RGX-202 data - Investing.com Australia
REGENXBIO (RGNX) Advances Gene Therapy Pipeline for Future Miles - GuruFocus
REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program - Chartmill
Aug PostEarnings: How REGENXBIO Inc stock performs during Fed tightening cycles2025 Major Catalysts & Smart Investment Allocation Tips - moha.gov.vn
REGENXBIO Inc. (RGNX) Stock Analysis: Exploring a 107% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Why REGENXBIO Inc. stock is trending among retail traders2025 Volume Leaders & Safe Capital Growth Stock Tips - Улправда
What hedge fund activity signals for REGENXBIO Inc. stockMarket Performance Report & Safe Swing Trade Setup Alerts - Улправда
Why REGENXBIO Inc. stock is recommended by analystsPortfolio Gains Report & Growth Focused Entry Reports - ulpravda.ru
How REGENXBIO Inc. stock trades during market volatilityJuly 2025 Levels & Daily Chart Pattern Signal Reports - Улправда
Is REGENXBIO Inc. stock gaining market share2025 Institutional Moves & Low Risk High Reward Ideas - ulpravda.ru
How REGENXBIO Inc. stock benefits from global expansionDividend Stock Watch & Start Your Free Trading Journey Today - ulpravda.ru
REGENXBIO (NASDAQ:RGNX) Sets New 1-Year HighStill a Buy? - MarketBeat
RegenXBio (RGNX) Gets a Buy from Bank of America Securities - The Globe and Mail
BofA Securities Raises Price Target on REGENXBIO to $28 From $20, Maintains Buy Rating - marketscreener.com
RegenXBio’s RGX-202: Promising Long-term Study for Duchenne Muscular Dystrophy - MSN
REGENXBIO updates Phase 1/2 data for Duchenne candidate - MSN
Trading the Move, Not the Narrative: (RGNX) Edition - Stock Traders Daily
Prospects for Regenxbio’s clemidsogene lanparvovec approval in Hunter syndrome - The Pharma Letter
REGENXBIO (NASDAQ:RGNX) Trading Down 3.8%Here's Why - MarketBeat
Regenxbio (RGNX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
REGENXBIO Inc. (NASDAQ:RGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Behavioral Patterns of RGNX and Institutional Flows - Stock Traders Daily
REGENXBIO (NASDAQ:RGNX) Hits New 1-Year HighWhat's Next? - MarketBeat
Assenagon Asset Management S.A. Purchases 132,942 Shares of REGENXBIO Inc. $RGNX - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Stifel raises Regenxbio stock price target to $45 on upcoming catalysts By Investing.com - Investing.com Australia
Stifel Maintains REGENXBIO (RGNX) Buy Recommendation - Nasdaq
REGENXBIO (NASDAQ:RGNX) Shares Up 9.2%What's Next? - MarketBeat
Stifel Raises Price Target for Regenxbio (RGNX) to $45 | RGNX St - GuruFocus
Stifel raises Regenxbio stock price target to $45 on upcoming catalysts - Investing.com Nigeria
Decliners Report: How interest rate cuts could boost REGENXBIO Inc. stockQuarterly Profit Review & Risk Adjusted Buy/Sell Alerts - Улправда
Regenxbio Inc (RGNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):